ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Core Viewpoint - The market anticipates ARS Pharmaceuticals, Inc. (SPRY) will report a year-over-year decline in earnings due to lower revenues, with a focus on how actual results compare to estimates [1][2]. Earnings Expectations - The consensus EPS estimate for ARS Pharmaceuticals is a loss of $0.42 per share, reflecting a year-over-year change of -180.8% [3]. - Expected revenues for the upcoming quarter are $25.74 million, down 70.3% from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 6.5% lower, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for ARS Pharmaceuticals is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +39.90% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - The current Zacks Rank for ARS Pharmaceuticals is 3, indicating a potential for beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, ARS Pharmaceuticals was expected to post a loss of $0.45 per share but actually reported a loss of -$0.52, resulting in a surprise of -15.56% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Context - Another company in the Zacks Medical - Drugs industry, Profound Medical (PROF), is expected to post a loss of $0.27 per share, indicating a year-over-year change of -35% [18]. - Profound Medical's revenues are expected to be $7.65 million, up 83% from the previous year [18].